Does the media refer more to ANIK or ANVS?

In the previous week, Annovis Bio had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Annovis Bio and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Annovis Bio's score of 0.53 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JANX or ANIK?

In the previous week, Janux Therapeutics had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 9 mentions for Janux Therapeutics and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Janux Therapeutics' score of 1.34 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVTX or ANIK?

In the previous week, Anika Therapeutics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Avalo Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Avalo Therapeutics' score of 0.94 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ANIK or CVAC?

Anika Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 0.62%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Anika Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LXRX or ANIK?

In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Anika Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Anika Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Anika Therapeutics (ANIK) Competitors

$20.87 -0.23 (-1.09%)

As of 04:00 PM Eastern

Compare

ANIK vs. ANVS, JANX, AVTX, CVAC, and LXRX

Should you buy Anika Therapeutics stock or one of its competitors? Anika Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), Janux Therapeutics (JANX), Avalo Therapeutics (AVTX), CureVac (CVAC), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anika Therapeutics compare to Annovis Bio?

Anika Therapeutics (NASDAQ:ANIK) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Anika Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 0.62%. Annovis Bio has a consensus price target of $11.33, suggesting a potential upside of 551.34%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Annovis Bio	N/A	-685.98%	-258.77%

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

In the previous week, Annovis Bio had 2 more articles in the media than Anika Therapeutics. MarketBeat recorded 5 mentions for Annovis Bio and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Annovis Bio's score of 0.53 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Anika Therapeutics beats Annovis Bio on 9 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Janux Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24M	46.41	-$113.62M	-$1.64	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

In the previous week, Janux Therapeutics had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 9 mentions for Janux Therapeutics and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Janux Therapeutics' score of 1.34 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Janux Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Anika Therapeutics	-3.14%	0.20%	0.15%

Janux Therapeutics currently has a consensus price target of $36.46, suggesting a potential upside of 100.12%. Anika Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 0.62%. Given Janux Therapeutics' higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Anika Therapeutics beats Janux Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Anika Therapeutics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Anika Therapeutics and 2 mentions for Avalo Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Avalo Therapeutics' score of 0.94 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics has higher revenue and earnings than Avalo Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	17,579.73	-$78.26M	-$4.37	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalo Therapeutics currently has a consensus target price of $45.10, suggesting a potential upside of 133.20%. Anika Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 0.62%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Avalo Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Avalo Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Anika Therapeutics	-3.14%	0.20%	0.15%

Avalo Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Summary

Anika Therapeutics beats Avalo Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Anika Therapeutics compare to CureVac?

Anika Therapeutics (NASDAQ:ANIK) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

CureVac has a net margin of 199.92% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
CureVac	199.92%	-23.03%	-19.09%

Anika Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

CureVac has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Anika Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Anika Therapeutics and 0 mentions for CureVac. Anika Therapeutics' average media sentiment score of 1.44 beat CureVac's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Anika Therapeutics	Positive
CureVac	Neutral

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Anika Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 0.62%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Anika Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Anika Therapeutics beats CureVac on 11 of the 17 factors compared between the two stocks.

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, indicating a potential upside of 102.22%. Anika Therapeutics has a consensus price target of $21.00, indicating a potential upside of 0.62%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 3 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 1.44 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Anika Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Anika Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Anika Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Anika Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$41.47M	24.14	-$50.34M	-$0.15	N/A
Anika Therapeutics	$120.65M	2.31	-$10.88M	-$0.27	N/A

Anika Therapeutics has a net margin of -3.14% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Anika Therapeutics' return on equity of 0.20% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Anika Therapeutics	-3.14%	0.20%	0.15%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Anika Therapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$279.30M	$3.92B	$7.12B	$12.85B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-77.29	11.69	272.89	25.51
Price / Sales	2.31	1,396.47	686.41	123.12
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.10	16.81	11.06	6.34
Net Income	-$10.88M	-$22.71M	$3.47B	$349.45M
7 Day Performance	-2.20%	2.89%	1.28%	-0.10%
1 Month Performance	8.25%	13.06%	8.29%	4.37%
1 Year Performance	122.49%	55.07%	24.29%	14.92%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	2.9352 of 5 stars	$20.87 -1.1%	$21.00 +0.6%	+124.9%	$279.30M	$120.65M	N/A	300	Positive News
ANVS Annovis Bio	2.7792 of 5 stars	$1.81 +3.1%	$11.67 +546.4%	-25.9%	$75.85M	N/A	N/A	3	Analyst Upgrade
JANX Janux Therapeutics	2.8769 of 5 stars	$18.89 +1.5%	$36.46 +93.1%	-20.6%	$1.15B	$24M	N/A	30
AVTX Avalo Therapeutics	2.8533 of 5 stars	$19.76 +2.6%	$45.10 +128.2%	+110.9%	$1.07B	$59K	N/A	40
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, JANX, AVTX, CVAC, and LXRX

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to Janux Therapeutics?

Summary

How does Anika Therapeutics compare to Avalo Therapeutics?

Summary

How does Anika Therapeutics compare to CureVac?

Summary

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, JANX, AVTX, CVAC, and LXRX

How does Anika Therapeutics compare to Annovis Bio?

Do analysts prefer ANIK or ANVS?

Is ANIK or ANVS more profitable?

Do institutionals & insiders hold more shares of ANIK or ANVS?

Which has higher valuation & earnings, ANIK or ANVS?

Which has more risk and volatility, ANIK or ANVS?

Does the media refer more to ANIK or ANVS?

Summary

How does Anika Therapeutics compare to Janux Therapeutics?

Which has more volatility & risk, JANX or ANIK?

Which has higher earnings & valuation, JANX or ANIK?

Does the media favor JANX or ANIK?

Do institutionals and insiders hold more shares of JANX or ANIK?

Is JANX or ANIK more profitable?

Do analysts rate JANX or ANIK?

Summary

How does Anika Therapeutics compare to Avalo Therapeutics?

Does the media favor AVTX or ANIK?

Which has higher valuation and earnings, AVTX or ANIK?

Do institutionals & insiders hold more shares of AVTX or ANIK?

Do analysts recommend AVTX or ANIK?

Is AVTX or ANIK more profitable?

Which has more risk & volatility, AVTX or ANIK?

Summary

How does Anika Therapeutics compare to CureVac?

Is ANIK or CVAC more profitable?

Which has more risk & volatility, ANIK or CVAC?

Which has higher valuation & earnings, ANIK or CVAC?

Does the media prefer ANIK or CVAC?

Do institutionals and insiders hold more shares of ANIK or CVAC?

Do analysts rate ANIK or CVAC?

Summary

How does Anika Therapeutics compare to Lexicon Pharmaceuticals?

Do analysts rate LXRX or ANIK?

Does the media refer more to LXRX or ANIK?

Which has more volatility & risk, LXRX or ANIK?

Which has higher earnings and valuation, LXRX or ANIK?

Is LXRX or ANIK more profitable?

Do institutionals & insiders have more ownership in LXRX or ANIK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools